NCT03590275 - Observational Retrospective Study of Evaluation of Prognostic Factors in Advanced Pancreatic Cancer Patients Treated With FOLFIRINOX | Biotech Hunter

Enrollment

343

Participants

Timeline

Start Date

October 2, 2017

Primary Completion Date

January 18, 2018

Study Completion Date

June 30, 2018

Conditions

Pancreatic Cancer Non-resectable

Interventions

DRUG

FOLFIRINOX

Patients treated with first-line FOLFIRINOX (oxaliplatin + irinotecan + lederfolin + 5-fluorouracil) as per clinical practice were included in the study

Trial Locations (7)

10060

Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia FPO - IRCSS, Candiolo

10126

P.O. Molinette Oncologia 1, Torino

10128

A.O. Ordine Mauriziano, Torino

13875

Oncologia ASL BI, Ponderano

28922

ASL VCO, Ospedale Castelli Verbania, Verbania

47014

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola

56012

A.O. Universitaria Pisana - Pisa (Pi) Oncologia Medica, Pisa

All Listed Sponsors

lead

Azienda Ospedaliero, Universitaria Pisana

OTHER